SUMMARY -Multiple sclerosis (MS) is a multicomponent disease characterized by infl ammation, neurodegeneration, and cancellation of the central nervous system recovery mechanisms. Th e cause of MS is still unknown, but it is undeniable that genetic, environmental and immune factors are involved in the etiopathogenesis of this complex and heterogeneous disease. From the aspect of immunopathogenesis, until recently the opinion prevailed that autoreactive T lymphocytes played a major role, the activation of which is a key step in MS. Th e knowledge of the eff ector and regulatory roles of B cells supports a new concept of MS immunopathogenesis that is based on the highly complex interaction of T and B cells, with B cells actively participating in cellular immunity by directing the intensity and quality of cellular immune response. Th e mechanisms of B cell activity in MS immunopathogenesis are multiple and include antigen presentation and T cell costimulation, cytokine secretion, antibody synthesis, and formation of ectopic lymphoid B cell aggregates in the intrameningeal spaces. Th e importance of B cells has been confi rmed by modern therapeutic options for the treatment of MS. 
Pathogenesis of Multiple Sclerosis
Multiple sclerosis (MS) is an idiopathic chronic infl ammatory demyelinating disease of the central nervous system (CNS) the leading features of which are numerous demyelinating lesions known as plaques. MS was named after gliotic sclerozation of the lesions that appear during disease progression.
Risk Factors for Multiple Sclerosis -Genetic or Environmental Factors?
Th e cause of MS is still unknown. It is suspected that MS is a multicomponent disease mediated by the infection-induced autoimmune process superimposed on genetic predisposition. Th us, the interaction of genetic, environmental and immune factors is involved in the etiopathogenesis of this complex and heterogeneous disease. Research has shown that environmental factors play a signifi cant role in the pathogenesis of MS, including infections, especially Epstein-Barr virus (EBV), sun exposure, decreased vitamin D plasma levels, smoking, obesity and increased salt intake, although a fully clarifi ed causeand-eff ect relationship has not yet been proven. Th ere is, however, substantial evidence for autoimmune pathogenesis of MS. Th e proposed pathogenesis of MS is characterized by the migration of peripheral T and B cells in the CNS, where they react to one or more unidentifi ed myelin or neuronal antigens, and stimulate and maintain an infl ammatory process that causes demyelination, axon loss and end of neuronal dehydration 1 . Th e role of EBV in the development of MS is not suffi ciently investigated, but there is convincing evidence for latent EBV infection re-activation initiating an autoimmune cascade in MS.
Geographic variations in the incidence of MS can partially be explained by genetic factors. Th e infl uence of genetic factors in MS is confi rmed by 20 to 40 times higher prevalence among patients' fi rst-degree relatives than in the general population.
Multiple sclerosis is not a hereditary disease, although individuals exhibit polygenetic predisposition linked to HLA locus on 6p 21 chromosome involving polymorphism of DR2 gene. Recent studies have shown that variations in DR1 complex, as well as HLA-C genome, could aff ect the likelihood of MS. Th ese discoveries are associated with MS 'risk' genes discovered in the latest analysis of experimental autoimmune encephalomyelitis, which show that for 9 diff erent genes associated with MS (MS gene susceptibility), Bach 2, IL2ra, Irf8, Merkk, Odf3b, Plek, Rgs1, Slc30a7 and Th ada confi rmation can be made about their diff erential regulation in pathogenic CD4 T cells. Th is fi nding confi rms the inclusion of MS 'risk' genes in the pathophysiology in the animal model and exposes additional infl ammatory networks important for the development of the disease.
When known environmental factors such as exposure to EBV infection and smoking are added to genetic risk, a score can be obtained that can partially predict the risk of developing MS and demonstrate consistent discrimination in independent samples. However, such a score cannot yet predict the risk of conversion from clinically isolated syndrome to clinically defi nite MS.
Immunopathogenesis of Multiple Sclerosis
Th e current concept of the pathogenesis of MS involves the activation of potentially autoreactive CD4+ T lymphocytes as an initial and key event in its pathogenesis. Activated autoreactive T lymphocytes express on their surface adhesive molecules that enable them to bind to the endothelium-brain barrier (EBB). At the same time, activated T lymphocytes produce matrix metalloproteinase (MMP) enzymes that allow the creation of openings in EBB, thereby disrupting its semipermeability and consequently enabling activation of activated T lymphocytes in the cerebral parenchyma. When such lymphocytes within the CNS meet the myelin basic protein (MBP) presented by the microglia in the role of the antigen presenting cells of the CNS, the autoreactive T lymphocytes are reactivated and initiate the secretion of proinfl ammatory cytokines that contribute to further deterioration of the semipermeability of EBB and determine the formation of infl ammatory lesions 1,2 ( Fig. 1 ). Th us, the activation of autoreactive peripheral T lymphocytes is an initial event in the pathogenesis of MS. Simultaneously, it is a sort of enigma that has yet to be clarifi ed since there is still no answer to the question of why the activation of autoreactive T lymphocytes is possible at all. One of the key activating factors is the recognition of certain antigens on the surface of the antigen presenting cells (APC) that provide the necessary costimulation of T lymphocytes by providing a costimulatory signal. It is believed that most of these antigens are in the form of viral peptides, such as peptides derived from human herpes virus 6 (HHV6), EBV, and Chlamydia pneumoniae. Peptide fragments of these microorganisms activate autoreactive T lymphocytes specifi c to myelin basic protein (MBP), the most represented protein of the myelinic envelope via two mechanisms:
• molecular mimicry, and • damaging functional anergy in the infl ammatory environment For peripheral T lymphocyte activation, gene constitution of a person that is associated with HLA--DR2, DR15 and other DR molecules believed to contribute to molecular mimicry between virus and MBP peptides is also signifi cant 3 . Infl ammatory lesion pathognomonic to MS is demyelinating plaque. Th e formation of plaque begins with the accumulation of infl ammatory mononuclear cells that infi ltrate perivascular spaces and the surrounding white matter. Analysis of this infl ammatory infi ltrate has shown it to consist primarily of T and B cells. Importantly, however, the lymphocytic infi ltration does not aff ect the entire cerebral parenchyma but only in certain sites where the demyelinating plaque may be caused, although MBP is widely present. It is known that localization of lesions in MS may be extremely variable and is a very important factor that determines clinical presentation of the disease. Th e diff erence in the distribution of lesions among MS patients is another puzzle of the disease attributed to gene constitution of the patient (Fig. 2) .
In the demyelinating plaque, apart from demyelinization, axonal damage and oligodendrocyte destruction also occur through numerous processes involving free radicals, direct complement depletion, antibody complement activation, natural-killer cell (NKC) mediated cytotoxicity, myelin phagocytosis, protease secretion and oligodendrocyte apoptosis.
All eff ector mechanisms of the immune system are practically involved in the process of demyelinating plaque formation in MS, and it is considered that all of them are primarily orchestrated by autoreactive CD4+ T lymphocytes (Fig. 3) .
Th ese infl ammatory events in MS relapse on average last from several days to two weeks. Residual cells and oligodendrocyte precursors that are still present in the adult CNS are afterwards activated and remyelination of the unmyelinated axons begins, although the thickness of the newly formed myelin sheath can never be fully restored, causing the remyelinized fi bers to have slower conductivity of the nerve pulse compared to intact fi bers. Additionally, restored myelin sheath also diff ers in composition because it contains certain isoforms of MBP considered to be functionally insuffi cient and vulnerable to infl ammation.
Many abnormalities in the functioning of the immune system exist in MS, but the opinion that autoreactive T lymphocytes play the key role in MS pathogenesis predominated until recently. Lately, the concept of MS as an autoimmune disease mediated mostly by T reactive cells has been questioned primarily due to some key fi ndings related to B cells. Th e immunopathogenesis of MS was determined by an extremely complex interaction of T and B cells during which both types of cells actively participated in the pathogenic process.
As for the role of T lymphocytes, for more than thirty years, the fi nding has been known that CD4+ T lymphocytes after stimulation by antigen may be diff erentiated into two major subpopulations with a clearly defi ned cytokine secretion profi le. Th ese are Th 1 and Th 2 cells. Th 1 cells are primarily produced by interferon-γ (IFN-γ), which acts as the most potent macrophage activator in cellular immunity. Th e hypothesis that Th 1 cells play a major role in MS pathogenesis was prevalent at fi rst, but it was questioned with the discovery of T regulatory cells (the function of which is maintaining homeostasis in the immune system), and in particular Th 17 cells as a completely recently found subpopulation of CD4+ T discovered about ten years ago 5, 6 (Fig. 4) . Cytokine secretion of Th 17 cells is extremely polymorphic. Th e basic cytokine is interleukin 17 (IL-17), which is a highly potent proinfl ammatory cytokine that acts through its own IL-17 receptors of ubiquitous tissue distribution.
In the animal model of MS, experimental autoimmune encephalomyelitis (EAE), it has been demonstrated that TH17 cells are carriers of the infl ammatory process in MS, while Th 1 cells have a protective role, which contrasts the present concept of MS pathogenesis. Th e ratio between Th 17 and Th 1 cells determines whether the initiation of infl ammation and consequently formation of demyelinating plaques will occur. Th e infl ammation occurs when the ratio between Th 17 and Th 1 is greater than 1 because there is a disproportionate increase in the secretion of IL-17, which is at present considered to be the main mediator of autoimmune processes in the CNS 7 . Intriguingly, in the spinal cord, the infl ammation occurs when the relationship between Th 17 and Th 1 cells is less than 1, indicating that the main mediator of infl ammation in the spinal cord are Th 1 cells. Th e reasons for this paradoxical pathogenic process of autoimmunity in the brain and spinal cord are still unclear.
A recent discovery of MS pathogenesis is functional antagonism between Th 17 and T regulatory cells. Th 17 cells are highly proinfl ammatory, while T regulatory cells are immunosuppressive, i.e. immunotolerant, although, interestingly, both use the same factors of diff erentiation, i.e. transforming growth factor β (TGF-β) and interleukin 6 (IL-6). Th e involvement of TGF-β in the Th 17 cell diff erentiation process was surprising since TGF-β alone has antiinfl ammatory properties and induces activation of FOXP3 transcription factor, an essential factor for the generation of T regulatory lymphocytes. However, when found in the infl ammatory environment, near the proinfl ammatory cytokine IL-6, TGF-β changes functional characteristics and acts synergistically inducing Th 17 cell formation in a proinfl ammatory way 8 ( Fig. 5) .
Fig. 4. T-cell profi les involved in multiple sclerosis.
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Fig. 5. Functional antagonism between Th 17 and T regulatory cells.
For the activation of T lymphocytes, interaction with B cells that have the role of antigen presenting cells producing the costimulatory signals/molecules crucial for the activation of T lymphocytes is necessary. It is, however, important to point out that the interaction between T and B lymphocytes is direct, since it is accomplished through costimulatory molecules producing B lymphocytes, and two-way, since B lymphocytes provide T lymphocytes with costimulatory signal by means of antigen presentation (costimulatory molecules determine the extent of T lymphocyte expansion after activation), while T lymphocytes aff ect B cells via cytokines and surface ligands 9, 10 . Th e previously mentioned interaction has the potential for positive feedback and circulus vitiosus creation. Th e question remains which of these cells makes the crucial mistake of triggering the autoimmune process (Fig. 6) .
Th e Role of B Cells in Multiple Sclerosis Pathogenesis
Th e B cells are carriers of humoral immunity. Th eir role in modulation of the immune response is very complex and goes beyond the limits of humoral immunity. Th ey play an important role in the development and regulation of cellular immunity, and this does not imply only passive interaction with T cells. Th e B cells, with their regulatory and eff ector role, actively participate in cellular immunity, thus directing the intensity and quality of the cellular immune response.
One of the hypotheses of autoimmunity is generally the loss of immune tolerance. In MS patients, it is considered that there is a specifi c defi cit of the peripheral B cell immune tolerance, which contributes to the accumulation of autoreactive B cells in peripheral blood. Th e formation of autoreactive B cells is relatively common in healthy subjects, but in healthy subjects, unlike MS patients, the autoreactive B cells are removed and their accumulation does not escalate. Removal is done in two ways:
-on the periphery where autoreactive B cells are selected and removed prior to diff erentiation into mature cellular forms; and -in bone marrow where B cell clones that have expressed self-reactive antibodies are removed. Th is removal procedure of autoreactive B cells is absent in MS patients due to the loss of immune tolerance, resulting in their accumulation in peripheral blood.
Th e mechanism of action of B cells is multiple: -presentation of antigen and costimulation of T cells, -cytokine secretion, -antibody production, and -ectopic neolymphogenesis -implying the formation of ectopic lymphoid structures similar to follicles in intrameningeal spaces (Fig. 7) . Although the dominant role of T cells in MS pathogenesis is often stressed, B cells can contribute to the pathogenesis of MS in various ways, e.g., as antigen presenting cells that costimulate autoreactive T cells, as a source of autoantibodies to diff erent components of myelin, axon and neurons, which contributes to demyelination and axonal damage. Further, they serve as regulatory cells that secrete cytokines and thus aff ect
Fig. 6. Interaction with B cells is crucial for T cell activation (antigen-presenting cells).

Fig. 7. Multiple roles of B cells in multiple sclerosis pathophysiology.
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Cytokines production Antibodies production the activity of regulatory T cells by modulating T cell response. Th ere is another important role of B cells, and it is ectopic neolymphogenesis, which implies the formation of ectopic lymphoid structures similar to follicles found in the meninges of MS patients, called tertiary lymph nodes and containing B cells and plasma cells. It is believed that these intrameningeal follicles can be the source of latent EBV infection the potential role of which in MS development is not suffi ciently researched, but there is some evidence that repeating latent EBV infection might trigger the autoimmune cascade [11] [12] [13] [14] [15] .
Production of Antibodies
Th e presence of antibodies in the cerebrospinal fl uid (CSF) of MS patients is convincing evidence that B cells are involved in MS pathogenesis. In healthy individuals, antibodies are not synthesized within CNS; therefore, their presence in the CSF always refers to an autoimmune process. Th e synthesis of antibodies is in the domain of eff ector function of the B cells, which, upon diff erentiation into plasma cells, are responsible for the production of antibodies. Th e intrathecal synthesis and presence of IgG in CSF of MS patients was fi rst demonstrated by electrophoresis in 1942. Although they represent the 'gold standard' in MS diagnosis, oligoclonal bands (OCB) are not specifi c for MS. Th eir presence can also be found in infectious CNS diseases such as neuroborreliosis, herpes simplex encephalitis, HIV infection and subacute sclerosing panencephalitis. However, OCB in MS patients are a persistent fi nding (once provedforever present), while in other entities they are often a transitory phenomenon and mostly disappear after several weeks or months. Th e presence of two or more bands in the CSF and their simultaneous absence in the serum strongly supports the diagnosis of MS.
Studies have shown that OCB pattern diff ers among patients, suggesting that there is a specifi c B cell response in MS patients that is unique to each individual patient.
Although OCB and intrathecal antibody synthesis have been subject to numerous studies, their signifi cance in the pathogenesis, as well as their specifi city, or target autoantigens, have not yet been precisely defi ned. Among the autoantibodies which play a role in MS pathogenesis, most important are proteins involved in the composition of the myelin sheath, i.e. myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), myelin proteolipid protein (PLP) and myelin-associated protein (MAG).
Multiple Sclerosis and Epstein-Barr Virus -Subpial Cortical Pathology
Multiple sclerosis is often associated with EBV infection. Previous infectious mononucleosis caused by EBV increases the risk of MS development. It is believed that repeated reactivation of latent EBV infection might be a trigger for starting an autoimmune cascade. Studies have found that the source of latent EBV infection may be ectopic aggregates of B cellular follicles, so called ectopic tertiary lymphoid tissues (TLT) in the intrameningeal spaces.
Th e presence of ectopic B cellular follicles is an adverse prognostic factor because it is associated with an unfavorable outcome of the disease in terms of faster progression and faster development of disability. Patients with positive ectopic B cellular follicles before 50 years of age develop severe disability that implies dependence on wheelchairs (Figs. 8 and 9) . Multiple sclerosis was once considered a white matter disease, which is only partially true. Today we know that the immunopathologic substrate in MS includes focal and diff use changes aff ecting both the white and the gray matter. In addition to focal demyelination, pathologic changes in MS also imply signifi cant changes in the white and gray matter not aff ected by plaques (normal appearing white matter (NAWM) and normal appearing gray matter (NAGM)), then axonal damage and loss of neurons and atrophy of the brain, which is now considered an important predictor of permanent disability of the patient.
It is important to note that most of these changes are expressed in early relapsed-remitting phase of the disease, even if there is no signifi cant clinical correlation, while some pathologic features are characteristic of the progressive stage of the disease. Th is refers to subpial cortical pathology, which implies the formation of ectopic B cell follicles in the intrameningeal compartments, and is associated with aggressive course of the disease and rapid development of patient disability (Fig. 10) .
Dual Concept of Multiple Sclerosis Pathogenesis: Infl ammation and Neurodegeneration
Th e traditional belief of MS as an infl ammatory demyelinating disease driven by an autoimmune process increasingly opposes the theory that MS is actually a neurodegenerative disease, either primary or age-related. Studies show support for both scenarios; therefore, dual concept of MS pathogenesis is the most acceptable theory, according to which MS is actually a biphasic disease, with a relapsing potentially reversible phase of disease that correlates with infl ammatory demyelination, and secondary potentially irreversible phase of disease characterized by critical axonal loss. Infl ammatory changes are less pronounced in later stage, although the disease is showing increasing progression. Th is dissociation between the intensity of infl ammation and progressive development of neurological disability is an infl ammation-neurodegenerative paradox characteristic of MS and indicates transition to the irreversible phase of the disease. Numerous clinical, neuropathological and neuroimaging studies have attempted to defi ne the mutual association of infl ammatory and progressive MS phases. It has long been known that early relapses aff ect long-term disability in MS, but there are still doubts and ambiguities what are the triggers for conversion of the relapsing remitting MS into the secondary progressive form. Some MS epidemiological studies have shown certain limitations to the infl uence of the infl ammatory phase of the disease on the progression of disability, stating that the relapsing and neurodegenerative phases of MS are mutually independent. Th e predictive value of disability development, in addition to the number of relapses, may also have the age, sex, residual defi cit after the fi rst relapse, time to second relapse and total number of relapses in the fi rst two years, and the duration of remission between relapses [16] [17] [18] [19] . Although the impact of relapses on progression is controversial, MS ultimately results in unsustainable progressive phase with permanent disability of the patient 20 . Th e dual concept of the pathogenesis of MS essentially determines the beginning of treatment. In the secondary progressive form, therapeutic options are exhausted and reduced only to symptomatic treatment. Th erefore, it is therapeutic imperative to act at an early stage of the disease and prevent conversion to the secondary progressive form, which is characterized by permanent disability of the patient (Fig. 11) .
